Encompass Health (EHC) has recently turned some heads among investors, not due to a single headline-making event, but because of steady price action that might be sending a signal. When a stock quietly outpaces the broader market over months, it’s worth asking if there’s more under the hood than meets the eye, or if investors are simply repositioning ahead of expected growth. For anyone watching the healthcare services sector, that kind of momentum doesn’t go unnoticed. Over the past year, Encompass Health has delivered a strong return, gaining 33%. There’s been consistent performance in the short term as well, with shares up over the past month and building further on a three-year gain of 186%. Alongside these price moves, the company has kept up positive trends in revenue and net income growth, making it a stock many are reconsidering. With that backdrop in place, the real question is whether today’s valuation offers a true buying opportunity, or if the market has already priced in what comes next for Encompass Health.

According to the most widely followed analyst consensus, Encompass Health is currently seen as undervalued by nearly 8%. This perspective is based on expectations for continued growth in demand, operational improvements, and long-term revenue expansion, all set against a backdrop of moderate risk factors.

The surge in the 65-plus population and persistent undersupply of inpatient rehabilitation beds are driving high and still-unmet demand for Encompass Health's core services. Ongoing hospital openings and bed expansions position the company to capture significant incremental patient volume, supporting higher revenue growth for years to come.

Want to know if this valuation is really as compelling as it sounds? Behind the narrative are bold projections for revenue, margins, and a future profit multiple that rivals market leaders. What numbers are analysts using to justify this upside? Could they be missing something? The answers might just surprise you.

Result: Fair Value of $137.42 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent labor shortages and regulatory changes could undermine growth expectations. This may put pressure on margins and alter the bullish outlook for Encompass Health.

Find out about the key risks to this Encompass Health narrative.

While analysts see upside, our DCF model paints a more optimistic picture. This approach estimates future cash flows and suggests the stock is trading well below its potential value. Are the market’s worries overblown?

Look into how the SWS DCF model arrives at its fair value.

Stay updated when valuation signals shift by adding Encompass Health to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.

If you see things differently or want to dive deeper into the data yourself, it’s quick and easy to build your own take in just a few minutes. Do it your way.

A great starting point for your Encompass Health research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Why stop with just one opportunity? Access unique market insights with strategies that could unlock the next wave of growth or yield for your portfolio. If you want to move ahead of the crowd, here are three types of stocks you should consider now.

Tap into tomorrow’s artificial intelligence breakthroughs ahead of the mainstream by checking out AI penny stocks shaking up everything from healthcare to everyday tech.

Boost your income stream with companies offering 3%;elm:context_link;itc:0;sec:content-canvas\\" class=\\"link \\">dividend stocks with yields > 3% and a history of rewarding shareholders through consistent cash payouts.

Spot rare bargains hiding in plain sight among undervalued stocks based on cash flows that could offer major upside before the rest of the market catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include EHC.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com